Polymyxin B · POLYMYXIN B SULFATE 500000 [USP'U]/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intrathecal; Intravenous; Ophthalmic · Eugia US LLC
NDC 55150-0234-10 · 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Eugia US LLC | POLYMYXIN B SULFATE 500000 [USP'U]/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Polymyxin B — NDC 55150-0234-10," retrieved September 3, 2026, https://drugdashboards.com/drug/55150023410.
Free to cite with attribution — see how the data is put together.